Key facts
- This page summarizes Nicole Vitullo's Form 4 filing for Esperion Therapeutics, Inc. (ESPR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Jun 2025, 16:07.
Nicole Vitullo - 29 May 2025 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)
- Reporting relationship
- Director
- Issuer ticker
- ESPR
- Reported as of
- 29 May 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2025, 16:07:03 UTC
- Prior SEC filing
- 24 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sheldon L. Koenig, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Nicole Vitullo filed Form 4 for Esperion Therapeutics, Inc. (ESPR) on 02 Jun 2025.
Change
- Previous filing in this sequence was filed on 24 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001196863
Primary reporting owner
VITULLO NICOLE
- Relationship
- Director
- Address
- C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR
- Signature
- /s/ Sheldon L. Koenig, by power of attorney
- Signature date
- 02 Jun 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ESPR
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +88,000
- Change %
- Price
- $0.000000
- Shares after
- 88,000
- Date
- 29 May 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 88,000
- Exercise price
- $0.8700
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025.